ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1992

Tolerance of Methotrexate Coadministered with Pegloticase in Patients with Uncontrolled Gout: Findings from MIRROR RCT
Abstract Number: 1095

Tolerance of non-TNF α treatments in patient with an inflammatory rheumatic (IRD) and autoimmune demyelinating diseases: French retrospective cases series
Abstract Number: 0688

Total lung capacity is predictive of disease severity and survival in systemic sclerosis: a longitudinal analysis in 2347 patients from the French National Cohort Study
Abstract Number: 0600

Toward a Consensus-Based Definition of Difficult-to-Treat Systemic Lupus Erythematosus: A Multinational Survey of Clinicians from the MENA Region
Abstract Number: 1778

Towards an Earlier and Accurate Diagnosis of Connective Tissue Disease-related Interstitial Lung Disease: TGFB Isoform Genes as Upcoming Biomarkers
Abstract Number: 2100

Trabecular Bone Texture is Associated with Structural and Pain Progression in Later Stages of Knee Osteoarthritis: Longitudinal Data from the FNIH OAI Cohort
Abstract Number: 2089

Traction Therapy May Improve Hand Function in Those with Distal Interphalangeal Osteoarthritis
Abstract Number: 0058

Training for increased inflammatory arthritis in mice is not modulated by type 1 interferon
Abstract Number: 2168

Training Objective Structured Clinical Examinations in a Clinical Immunology department: Expectations and Perceptions of Medical students at Graduating Level
Abstract Number: 0879

Trajectories and risk factors of interstitial lung disease in limited cutaneous systemic sclerosis from the EUSTAR cohort
Abstract Number: 2097

Trajectories of psychological symptoms during an 18-month Diet + Exercise intervention in overweight or obese adults with osteoarthritis
Abstract Number: 0081

Trans-endothelial Trafficking of Fibroblast-like Synoviocytes Amplifies Synovial Inflammation in Rheumatoid Arthritis
Abstract Number: 1228

Transcending barriers to pain care in rural America: a pragmatic comparative effectiveness trial of evidence-based, on-demand, digital behavioral treatments for chronic pain
Abstract Number: 1821

Transcriptiomics of tear RNA from children with active and inactive chronic anterior uveitis
Abstract Number: 1839

Transcriptional Profiling of Whole Blood and Kidney Biopsy Samples from Lupus Nephritis and IgA Nephropathy Patients Suggests Different Disease Pathways

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].